GlassScriptPhysician profile
Anthony Morlandt
NPI 1649473638
$18,544.96
in general payments reported to CMS, 2019-2025
11 companies · $752 in 2025
The $752 reported for 2025 was more than what 79% of Oral & Maxillofacial Surgery providers received nationally (typical 2025 total: $184).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,545 · 2021: $1,832 · 2022: $573 · 2023: $489 · 2024: $250 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kls-Martin L.P. | $17,227.48 | 2019-2025 | |
| Axogen | $679.06 | 2021-2025 | Axoguard Nerve Cap, Axoguard Nerve Protector, Axoguard Ha+ Nerve Protector |
| Depuy Synthes Sales INC. | $220.77 | 2020-2021 | |
| Aroa Biosurgery Incorporated | $219.29 | 2023 | |
| Stryker Corporation | $108.82 | 2022-2023 | Vsp System, Vsp Cranial |
| Biohorizons Implant Systems INC. | $21.81 | 2021 | |
| Brainlab, INC. | $21.34 | 2021-2022 | |
| Smith+Nephew, INC. | $18.03 | 2025 | Versajet |
| Access Pro Medical, LLC | $17.15 | 2025 | Matriderm |
| Kerecis Limited | $11.21 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Morlandt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.